Yet, radioresistant stem cells present in the tumor contribute to therapeutic failure to radiotherapy, poor prognosis, relapses, and metastasis in patients.5 It is affirmed that CD44 and CD133 markers are the major lung cancer stem cell biomarkers.6,7 CD44 markers are found to be implicated in signaling cascades that are concerned with tumor progression and initiation and take part in cell migration. The gene discussed is CD44; the disease is lung cancer.